

## Medical Policy Manual **Draft Revised Policy: Do Not Implement**

### Givosiran (Givlaari®)

#### IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

**The proposal is to add text/statements in red and to delete text/statements with strikethrough:  
POLICY**

#### INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Givlaari is indicated for the treatment of adults with acute hepatic porphyria (AHP).

All other indications are considered experimental/investigational and not medically necessary.

#### DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

**For initial requests:** Elevated porphobilinogen (PBG) in the urine confirmed by a PBG quantitative random urine test, or an elevated porphyrin level (plasma or fecal).

#### **COVERAGE CRITERIA FOR INITIAL APPROVAL**

##### **Acute Hepatic Porphyria**

Authorization of 12 months may be granted for treatment of acute hepatic porphyria when all of the following criteria are met:

- The member is actively symptomatic (e.g., porphyria attacks requiring hospitalization, urgent healthcare visits, or intravenous hemin administration), or the member has experienced 4 or more porphyria attacks per year.
- The member has an elevated urine porphobilinogen (PBG), or an elevated porphyrin level (plasma or fecal).

#### CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment of an indication listed in the coverage criteria section III for members who are experiencing benefit from therapy while receiving Givlaari (e.g., reduction in porphyria attacks that required hospitalizations, urgent healthcare visit, or intravenous hemin administration).

#### **APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS**



**BlueCross BlueShield  
of Tennessee**

# ***Policy***

## **Medical Policy Manual    Draft Revised Policy: Do Not Implement**

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

### **ADDITIONAL INFORMATION**

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

### **REFERENCES**

1. Givlaari [package insert]. Cambridge, MA: Alnylam Pharmaceuticals; April 2024.

### **EFFECTIVE DATE**

**ID\_CHS**